Tumor Antigen by Immunoassay - CA 125

CA 125 immunoassay is covered for baseline, monitoring, and surveillance in patients with confirmed epithelial ovarian carcinoma and certain related gynecologic or peritoneal malignancies, including use after surgery and chemotherapy and as a response marker in advanced or recurrent disease. It is not covered for diagnostic evaluation of symptomatic patients or to establish the differential diagnosis of a pelvic mass; post-treatment monitoring requires three serial measurements in the first month to determine CA 125 half-life and surveillance should follow the specified 3-/6-/12-month schedule.

"CA 125 testing is covered for patients with confirmed epithelial ovarian carcinoma for baseline assessment, monitoring response to therapy, and surveillance for recurrence."

Sign up to see full coverage criteria, indications, and limitations.